As the S&P 500 and Nasdaq Composite continue to reach record highs, fueled by strong tech performances and rate cut anticipations, investors are keenly watching the market for opportunities. In this environment, identifying stocks that appear undervalued relative to their intrinsic value could be particularly compelling. Top 10 Undervalued Stocks Based On Cash Flows In The United States Name Current Price Fair Value (Est) Discount (Est) Hanover Bancorp (NasdaqGS:HNVR) $16.18 $31.97 49.4% Lazard (NYSE:LAZ) $39.91 $78.79 49.3% Victory Capital Holdings (NasdaqGS:VCTR) $47.30 $92.71 49% Array Technologies (NasdaqGM:ARRY) $9.44 $18.59 49.2% Daqo New Energy (NYSE:DQ) $15.48 $30.43 49.1% AppLovin (NasdaqGS:APP) $84.71 $165.42 48.8% Hexcel (NYSE:HXL) $64.11 $127.33 49.7% APi Group (NYSE:APG) $36.48 $71.48 49% Hecla Mining (NYSE:HL) $5.27 $10.53 49.9% Zillow Group (NasdaqGS:ZG) $46.35 $92.65 50% Click here to see the full list of 180 stocks from our Undervalued US Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Alnylam Pharmaceuticals Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference, with a market capitalization of approximately $32.27 billion. Operations: The company generates its revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, totaling approximately $2.00 billion. Estimated Discount To Fair Value: 48% Alnylam Pharmaceuticals, currently priced at US$254.74, is significantly undervalued based on DCF analysis with a fair value estimate of US$489.82, indicating it trades below fair value by more than 20%. Recent positive Phase 3 study results for vutrisiran suggest potential future revenue streams and market expansion, supporting its high expected revenue growth rate of 19.5% per year compared to the market's 8.7%. Despite this potential, the stock remains highly volatile and has seen significant insider selling recently. Our earnings growth report unveils the potential for significant increases in Alnylam Pharmaceuticals' future results. Click to explore a detailed breakdown of our findings in Alnylam Pharmaceuticals' balance sheet health report. NasdaqGS:ALNY Discounted Cash Flow as at Jul 2024 DoorDash Overview: DoorDash, Inc. operates a global commerce platform linking merchants, consumers, and independent contractors, with a market capitalization of approximately $44.59 billion. Operations: The company generates its revenue primarily from internet information services, totaling approximately $9.11 billion. Estimated Discount To Fair Value: 40.4% DoorDash, currently priced at US$108.95, appears undervalued with a DCF-based fair value estimate of US$182.94, trading below fair value by more than 20%. Recent index adjustments reflect mixed market perceptions, though its addition to the Russell Top 200 suggests some positive sentiment. Despite challenges in finalizing acquisition deals like Deliveroo, strategic partnerships with companies like Academy Sports and Ulta Beauty enhance its service offerings and market presence. Revenue is expected to grow at 12.7% annually, outpacing the U.S market forecast of 8.7%. However, significant insider selling over the past three months could indicate caution among stakeholders. Insights from our recent growth report point to a promising forecast for DoorDash's business outlook. Delve into the full analysis health report here for a deeper understanding of DoorDash. NasdaqGS:DASH Discounted Cash Flow as at Jul 2024 Zillow Group Overview: Zillow Group, Inc. operates a portfolio of real estate brands through mobile applications and websites in the United States, with a market capitalization of approximately $10.97 billion. Operations: The company generates approximately $2.01 billion in revenue from its internet information services. Estimated Discount To Fair Value: 50% Zillow Group, trading at US$46.35, is significantly undervalued based on cash flows with a fair value estimate of US$92.65. Despite a net loss in Q1 2024, revenue increased to US$529 million from US$469 million year-over-year, showing resilience and potential for growth. The company's strategic initiatives like the Fair Housing Classifier highlight its commitment to innovation and market integrity. Forecasted annual revenue growth of 10.7% outstrips the U.S market average of 8.7%, positioning Zillow for improved profitability within three years. The analysis detailed in our Zillow Group growth report hints at robust future financial performance. Get an in-depth perspective on Zillow Group's balance sheet by reading our health report here. NasdaqGS:ZG Discounted Cash Flow as at Jul 2024 Where To Now? Unlock our comprehensive list of 180 Undervalued US Stocks Based On Cash Flows by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ALNYNasdaqGS:DASH and NasdaqGS:ZG. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...